This fact sheet gives a brief overview of the key facts regarding corruption in the pharmaceutical supply chain. It focuses on unethical practices in the medicines supply chain, factors contributing to pharmaceutical corruption, the impact of corruption, and the response of the WHO
"This report presents the findings of the first phase of the [World Health Organization's] national Good Governance for Medicines programme in Jordan. The assessment aims to obtain a picture of the level of transparency and potential vulnerability to corruption in the public pharmaceutical sector using WHO’s assessment instrument. In Jordan, the assessment looked at six functions: medicines registration, inspection of pharmaceutical establishments, promotion, selection, procurement and distribution"
"This report presents the findings of the first phase of the [World Health Organization's] national Good Governance for Medicines programme in Lebanon. The assessment aims to obtain a picture of the level of transparency and potential vulnerability to corruption in the public pharmaceutical sector using WHO’s assessment instrument. In Lebanon, the assessment looked at six functions: medicines registration, inspection of pharmaceutical establishments, promotion, selection, procurement and distribution"
"This report presents the findings of the first phase of the [World Health Organization's] national Good Governance for Medicines programme in the Syrian Arab Republic. The assessment aims to obtain a picture of the level of transparency and potential vulnerability to corruption in the public pharmaceutical sector using WHO’s assessment instrument. In the Syrian Arab Republic, the assessment looked at eight functions: medicines registration, licensing of pharmaceutical establishments, inspection of pharmaceutical establishments, promotion, selection, clinical trials, procurement and distribution"
Information is an integral part of healthcare: the need for patients to give informed consent is the basis of all care and treatment. For patients to be able to make informed choices they need information that is reliable, comparative and adapted to users, and that is not linked to advertising and drug promotion
This module defines the respective roles of the public, private (for-profit) and NGO (not-for-profit) sectors in the financing and provision of psychotropic medicines. It identifies organizational arrangements in these sectors to meet the objectives of access. The guidance sets an agenda for capacity building and organizational development and provides guidance for prioritizing expenditure and making decisions on resource allocation
Note: This module is part of a guidance package that consists of a series of interrelated user-friendly modules that are designed to address the wide variety of needs and priorities in mental health policy development and service planning. Its recommended for use by policy makers, service planners representatives or associations of families and carers of people with mental disorders
This article provides estimates of the prevalence, severity, and treatment of mental disorders from the WHO World Mental Health Survey which included data from 14 countries (six less developed, eight developed) by conducting 60,463 face-to-face interviews with adult individuals representing the general population. The article concludes by recommending careful consideration of mild cases and a reallocation of treatment resources; however, it also acknowledges that structural barriers may exist to this reallocation
The Journal of the American Medical Association (JAMA), Vol 291, No 21
This annotated bibliography has been prepared in an effort to provide policy makers, technical personnel and other stakeholders with comprehensive information on the costs of interventions and impact of HIV on health systems. The documents included in the bibliograpy focus on those aspects of the pandemic most related to economic impact, financing and resource allocation, costing, health system strengthening, scaling up antiretroviral therapy, surveillance systems, and programme monitoring and evaluation. The bibliography describes 101 publications describing work done from 1995 onwards as well as a directory of web resources. The bibliography is not a comprehensive reveiw, but is rather intended to highlight current information in the field of HIV and health systems strengthening
This policy brief looks at the range of resources currently being expended to address the HIV/AIDS epidemic in resource poor settings (developing countries and countries in transition). It includes bilateral, multilateral and private sector support as well as domestic spending by recipient country governments. There are also reports on philanthropic giving by the business community and pharmaceutical companies. There are estimates of global funding requirements and estimates on current spending. It is noted that tracking mechanisms are often ill-equipped to provide current data on spending patterns. Little is known about exact ways in which the money is spent